Price movement over the last 24 hours
ARK Genomic Revolution ETF vs Wahed FTSE USA Shariah ETF — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while Wahed FTSE USA Shariah ETF trades at $71.7. Which is the better fit depends on your goals.
| ARKG | HLAL | |
|---|---|---|
Sector | Sector/Thematic | Sector/Thematic |
52-Week High | $43.57 | $73.60 |
52-Week Low | $23.09 | $53.83 |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
HLAL trades at $72.05, up 0.67% with a bullish technical signal from moving averages. The stock shows neutral momentum oscillators with key support at $71 and resistance at $72. Financial ratios remain undisclosed in current data, requiring deeper fundamental analysis.
The bullish technical setup suggests potential upside if resistance breaks, but limited fundamental data warrants caution. Investors should await earnings reports and valuation metrics for clearer investment thesis development amid current information gaps.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →